Glycoxidation of histone proteins in autoimmune disorders

Clinica Chimica Acta

Volumn 450, Issue , 2015, Pages 25-30

  Mir, Abdul Rouf ^a   Moinuddin, ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Advance glycation end products (AGEs); Autoimmune diseases; Glycation; Histone proteins

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HISTONE; CHROMATIN;

AMINO ACID SEQUENCE; AUTOIMMUNE DISEASE; CONFORMATIONAL TRANSITION; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; GENE SILENCING; HISTONE GLYCOXIDATION; HISTONE MODIFICATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; CHEMISTRY; CHROMATIN; GLYCOSYLATION; METABOLISM;

ANIMALS; AUTOIMMUNE DISEASES; CHROMATIN; GLYCOSYLATION; HISTONES; HUMANS;

EID: 84938700882     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.07.029     Document Type: Review

References (104)

1. Kornberg R.D. Chromatin structure: a repeating unit of histones and DNA. Science 1974, 184:868-871.
2. Elgin S.C., Weintraub H. Chromosomal proteins and chromatin structure. Annu. Rev. Biochem. 1975, 44:725-774.
3. Luger K., Mäder A.W., Richmond R.K., Sargent D.F., Richmond T.J. Crystal structure of the nucleosome core particle at 2.8A resolution. Nature 1997, 389(6648):251-260.
4. Hansen J.C. Conformational dynamics of the chromatin fiber in solution: determinants, mechanisms and functions. Annu. Rev. Biophys. Biomol. Struct. 2002, 31:361-392.
5. Georgel P.T., Hansen J.C. Linker histone function in chromatin: dual mechanisms of action. Biochem. Cell Biol. 2001, 79(3):313-316.
6. Arents G., Burlingame R.W., Wang B.C., Love W.E., Moudrianakis E.N. The nucleosomal core histone octamer at 3.1A resolution: a tripartite protein assembly and a left-handed superhelix. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(22):10148-10152.
7. van Holde K.E. Chromatin 1988, Springer-Verlag, New York.
8. Bártová E., Krejcí J., Harnicarová A., Galiová G., Kozubek S. Histone modifications and nuclear architecture: a review. J. Histochem. Cytochem. 2008, 56(8):711-721.
9. Peterson C.L., Laniel M.A. Histones and histone modifications. Curr. Biol. 2004, 14(14):R546-R551.
10. Bannister A.J., Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011, 21(3):381-395.
11. Cohen I., Poreba E., Kamieniarz K., Schneider R. Histone modifiers in cancer: friends or foes?. Genes Cancer 2011, 2(6):631-647.
12. Talasz H., Wasserer S., Puschendorf B. Nonenzymatic glycation of histones in vitro and in vivo. J. Cell. Biochem. 2002, 85:24-34.
13. Guedes S., Vitorino R., Domingues M.R., Amado F., Domingues P. Glycation and oxidation of histones H2B and H1: in vitro study and characterization by mass spectrometry. Anal. Bioanal. Chem. 2011, 399(10):3529-3539.
14. Singh R., Barden A., Mori T., Beilin L. Advanced glycation end-products: a review. Diabetologia 2001, 44(2):129-146.
15. Chuah Y.K., Basir R., Talib H., Tie T.H., Nordin N. Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int. J. Inflamm. 2013, 403460.
16. Rabbani N., Thornalley P.J. Dicarbonyl proteome and genome damage in metabolic and vascular disease. Biochem. Soc. Trans. 2014, 42(2):425-432.
17. Salahuddin P., Rabbani G., Khan R.H. The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach. Cell. Mol. Biol. Lett. 2014, 19(3):407-437.
18. Nowotny K., Jung T., Höhn A., Weber D., Grune T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 2015, 5(1):194-222.
19. Cervantes-Laurean D., Jacobson E.L., Jacobson M.K. Glycation and glycoxidation of histones by ADP-ribose. J. Biol. Chem. 1996, 271(18):10461-10469.
20. Mir A.R., Uddin M., Alam K., Ali A. Methylglyoxal mediated conformational changes in histone H2A-generation of carboxyethylated advanced glycation end products. Int. J. Biol. Macromol. 2014, 69:260-266.
21. Dixit K., Khan M.A., Sharma Y.D., Moinuddin, Alam K. Physicochemical studies on peroxynitrite-modified H3 histone. Int. J. Biol. Macromol. 2010, 46(1):20-26.
22. Rahmanpour R., Bathaie S.Z. Histone H1 structural changes and its interaction with DNA in the presence of high glucose concentration in vivo and in vitro. J. Biomol. Struct. Dyn. 2012, 28(4):575-586.
23. Kuleva N.V., Fedorova M.A., Frolov A.A. Dynamics of rat hepatocyte histone glyoxidation after general x-ray irradiation. Tsitologiia 2006, 48(6):515-521.
24. Wondrak G.T., Cervantes-Laurean D., Jacobson E.L., Jacobson M.K. Histone carbonylation in vivo and in vitro. Biochem. J. 2000, 351(3):769-777.
25. Dixit K., Khan M.A., Sharma Y.D., Moinuddin, Alam K. Peroxynitrite-induced modification of H2A histone presents epitopes which are strongly bound by human anti-DNA autoantibodies: role of peroxynitrite-modified-H2A in SLE induction and progression. Hum. Immunol. 2011, 72(3):219-225.
26. Pashikanti S., Boissonneault G.A., Cervantes-Laurean D. Ex vivo detection of histone H1 modified with advanced glycation end products. Free Radic. Biol. Med. 2011, 50(10):1410-1416.
27. Hilz H., Adamietz P., Bredehors R., Wielckens K. ADP-ribosylation of nuclear proteins. Adv. Enzym. Regul. 1978, 17:195-211.
28. Hilz H., Wielckens K., Adamietz P., Bredehorst R., Kreymeier A. Functional aspects of mono- and poly(ADP-ribosyl)ation: subcellular distribution and ADP ribosyl turnover under conditions of repair and 'starvation'. Princess Takamatsu Symp. 1983, 13:155-163.
29. Adamietz P., Rudolph A. ADP-ribosylation of nuclear proteins in vivo: identification of histone H2B as a major acceptor for mono- and poly(ADPribose) in dimethyl sulfate-treated hepatoma AH 7974 cells. J. Biol. Chem. 1984, 259:6841-6846.
30. Kreimeyer A., Wielckens K., Adamietz P., Hilz H. DNA repair-associated ADPribosylation in vivo: modification of histone H1 differs from that of the principal acceptor proteins. J. Biol. Chem. 1984, 259:890-896.
31. Kreimeyer A., Adamietz P., Hilz H. Alkylation-induced mono(ADP-ribosyl)- histones H1 and H2B: hydroxylamine-resistant linkage in hepatoma cells. Biol. Chem. 1985, 366:537-544.
32. De Bellis D., Horowitz M.I. In vitro studies of histone glycation. Biochim. Biophys. Acta 1987, 926(3):365-368.
33. Lakatos Á., Jobst K. Histone glycosylation. Acta Biochim. Biophys. Hung. 1989, 24:355-359.
34. Jobst K., Lakatos A., Horvàth A. Glycohistones in diabetic human liver. Clin. Chim. Acta 1991, 200(2-3):231-232.
35. Lakatos A., Jobst K. Kinetics of histone protein glycation. Acta Biochim. Biophys. Hung. 1991-1992, 26(1-4):33-38.
36. Liebich H.M., Gesele E., Wirth C., Wöll J., Jobst K., Lakatos A. Non-enzymatic glycation of histones. Biol. Mass Spectrom. 1993, 22(2):121-123.
37. Gugliucci A. Advanced glycation of rat liver histone octamers: an in vitro study. Biochem. Biophys. Res. Commun. 1994, 203(1):588-593.
38. Lakatos A., Kis N., Jobst K. Differences in nonenzymatic glycation of histones. Acta Biochim. Pol. 1994, 41(4):429-432.
39. Gugliucci A., Bendayan M. Histones from diabetic rats contain increased levels of advanced glycation end products. Biochem. Biophys. Res. Commun. 1995, 212(1):56-62.
40. Jobst K., Lakatos A. The liver cell histones of diabetic patients contain glycation endproducts (AGEs) which may be lipofuscin components. Clin. Chim. Acta 1996, 256(2):203-204.
41. Bathaie S.Z., Moosavi-Movahedi A.A., Ranjbar B., Saboury A.A. The mechanistic study of the histone H1-DNA complex dissociation by sodium dodecyl sulphate. Colloids Surf. B: Biointerfaces 2003, 28:17-25.
42. Tarkka T., Yli-Mäyry N., Mannermaa R.M., Majamaa K., Oikarinen J. Specific non-enzymatic glycation of the rat histone H1 nucleotide binding site in vitro in the presence of AlF4-. A putative mechanism for impaired chromatin function. Biochim. Biophys. Acta 1993, 1180(3):294-298.
43. Shaw C.A., Kette S.D., Davidson R.M., Seneff S. Aluminum's Role in CNS-immune system interactions leading to neurological disorders. Immunome Res. 2013, 9:069.
44. Jacobson E.L., Cervantes-Laurean D., Jacobson M.K. Glycation of proteins by ADP-ribose. Mol. Cell. Biochem. 1994, 138(1-2):207-212.
45. Alam S., Arif Z., Alam K. Glycated-H2A histone is better bound by serum anti-DNA autoantibodies in SLE patients: glycated-histones as likely trigger for SLE?. Autoimmunity 2015, 48(1):19-28.
46. Dyer D.G., Blackledge J.A., Thorpe S.R., Baynes J.W. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J. Biol. Chem. 1991, 266(18):11654-11660.
47. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991, 11(1):81-128.
48. Thornalley P.J. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-a role in pathogenesis and antiproliferative chemotherapy. Gen. Pharmacol. 1996, 27(4):565-573.
49. Roberts M.J., Wondrak G.T., Laurean D.C., Jacobson M.K., Jacobson E.L. DNA damage by carbonyl stress in human skin cells. Mutat. Res. 2003, 522(1-2):45-56.
50. Ansari N.A., Dash D. Biochemical studies on methylglyoxal-mediated glycated histones: implications for presence of serum antibodies against the glycated histones in patients with type 1 diabetes mellitus. ISRN Biochem. 2013, 198065.
51. Ashraf J.M., Ahmad S., Rabbani G., Hasan Q., Jan A.T., Lee E.J., Khan R.H., et al. 3-Deoxyglucosone: a potential glycating agent accountable for structural alteration in H3 histone protein through generation of different AGEs. PLoS ONE 2015, 10(2):e0116804.
52. Ashraf J.M., Ahmad S., Rabbani G., Jan A.T., Lee E.J., Khan R.H., et al. Physicochemical analysis of structural alteration and advanced glycation end products generation during glycation of H2A histone by 3-deoxyglucosone. IUBMB Life 2014, 66(10):686-693.
53. Cervantes-Laurean D., Roberts M.J., Jacobson E.L., Jacobson M.K. Nuclear proteasome activation and degradation of carboxymethylated histones in human keratinocytes following glyoxal treatment. Free Radic. Biol. Med. 2005, 38(6):786-795.
54. Pashikanti S., de Alba D.R., Boissonneault G.A., Cervantes-Laurean D., Laurean D. Rutin metabolites: novel inhibitors of nonoxidative advanced glycation end products. Free Radic. Biol. Med. 2010, 48(5):656-663.
55. Stoynev G.A., Rebreva L.N., Ivanov I.G. Histone H1 as a reporter protein to investigate glycation in bacteria. Curr. Microbiol. 2004, 49(6):423-427.
56. Mironova R., Niwa T., Handzhiyski Y., Sredovska A., Ivanov I. Evidence for non-enzymatic glycosylation of Escherichia coli chromosomal DNA. Mol. Microbiol. 2005, 55(6):1801-1811.
57. Mironova R., Niwa T., Hayashi H., Dimitrova R., Ivanov I. Evidence for non-enzymatic glycosylation in Escherichia coli. Mol. Microbiol. 2001, 39(4):1061-1068.
58. Horiuchi S., Araki N., Morino Y. Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. Evidence for the presence of a common structure. J. Biol. Chem. 1991, 266(12):7329-7332.
59. Makita Z., Vlassara H., Cerami A., Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J. Biol. Chem. 1992, 267(8):5133-5138.
60. Nagai R., Fujiwara Y., Mera K., Yamagata K., Sakashita N., Takeya M. Immunochemical detection of Nepsilon-(carboxyethyl)lysine using a specific antibody. J. Immunol. Methods 2008, 332(1-2):112-120.
61. Yan S.F., Ramasamy R., Schmidt A.M. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4(5):285-293.
62. Khatoon F., Moinuddin, Alam K., Ali A. Physicochemical and immunological studies on 4-hydroxynonenal modified HSA: implications of protein damage by lipid peroxidation products in the etiopathogenesis of SLE. Hum. Immunol. 2012, 73(11):1132-1139.
63. Khan M.A., Dixit K., Jabeen S., Moinuddin, Alam K. Impact of peroxynitrite modification on structure and immunogenicity of H2A histone. Scand. J. Immunol. 2009, 69(2):99-109.
64. Chikazawa M., Otaki N., Shibata T., Miyashita H., Kawai Y., Maruyama S., et al. Multispecificity of immunoglobulin M antibodies raised against advanced glycation end products: involvement of electronegative potential of antigens. J. Biol. Chem. 2013, 288(19):13204-13214.
65. Ching K.H., Burbelo P.D., Tipton C., Wei C., Petri M., Sanz I., et al. Two major autoantibody clusters in systemic lupus erythematosus. PLoS ONE 2012, 7(2):e32001.
66. Sherer Y., Gorstein A., Fritzler M.J., Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin. Arthritis Rheum. 2004, 34(2):501-537.
67. Nienhuis H.L., Estra J., Smit A.J., Limburg P.C., Kallenberg C.G., Bijl M. AGE and their receptor RAGE in systemic autoimmune diseases: an inflammation propagating factor contributing to accelerated atherosclerosis. Autoimmunity 2009, 42(4):302-304.
68. Stummvoll G.H., Fritsch R.D., Meyer B., Hoefler E., Aringer M., Smolen J.S., et al. Characterisation of cellular and humoral autoimmune responses to histone H1 and core histones in human systemic lupus erythaematosus. Ann. Rheum. Dis. 2009, 68(1):110-116.
69. Alzolibani A.A., Al-Robaee A.A., Al-Shobaili H.A., Rasheed Z. 4-Hydroxy-2-nonenal modified histone-H2A: a possible antigenic stimulus for systemic lupus erythematosus autoantibodies. Cell. Immunol. 2013, 284(1-2):154-162.
70. Khan M.A., Dixit K., Arif Z., Moinuddin, Ashraf J.M., Alam K. Peroxynitrite-modified H3 histone is highly immunogenic and binds circulating SLE autoantibodies better than native DNA. Am. J. Biomed. Sci. 2013, 5(1):69-79.
71. Ruddy S., Harris E.D., Sledge C.B., Budd R.C., Sergent J.S., Kelley W.N. Kelley's Textbook of Rheumatology 2005, 1697-1704. Elsevier. 7th edition.
72. Shahab U., Ahmad S., Moinuddin, Dixit K., Habib S., Alam K., et al. Hydroxyl radical modification of collagen type II increases its arthritogenicity and immunogenicity. PLoS ONE 2012, 7(2):e31199.
73. Sunahori K., Yamamura M., Yamana J., Takasugi K., Kawashima M., Makino H. Increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum. 2006, 54(1):97-104.
74. de Groot L., Hinkema H., Westra J., Smit A.J., Kallenberg C.G., Bijl M., et al. Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease. Arthritis Res. Ther. 2011, 13(6):R205.
75. Khan M.A., Dixit K., Moinuddin Malik A., Alam K. Role of peroxynitrite-modified H2A histone in the induction and progression of rheumatoid arthritis. Scand. J. Rheumatol. 2012, 41:426-433.
76. Roep B.O., Peakman M. Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb. Perspect. Med. 2012, 2(4):a007781.
77. Rasheed Z., Kumar L., Sajid Prasad I., Ansari N.A., Ahmad R. Advanced glycation end products (AGEs) damaged IgG, a target for circulating autoantibodies in patients with type 1 diabetes mellitus. Open Glycosci. 2009, 2:1-8.
78. Ryan Brent J., Nissim Ahuva, Winyard Paul G. Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases. Redox Biol. 2014, 2:715-724.
79. Harshman S.W., Young N.L., Parthun M.R., Freitas M.A. H1 histones: current perspectives and challenges. Nucleic Acids Res. 2013, 41(21):9593-9609.
80. Bowman G.D., Poirier M.G. Post-translational modifications of histones that influence nucleosome dynamics. Chem. Rev. 2015, 115(6):2274-2295.
81. Luo X.G., Guo S., Guo Y., Zhang C.L. Histone Modification and Breast Cancer 2011, M. Gunduz (Ed.).
82. Abe R., Yamagishi S. AGE-RAGE system and carcinogenesis. Curr. Pharm. Des. 2008, 14(10):940-945.
83. Kuniyasu H., Chihara Y., Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol. Rep. 2003, 10:445-448.
84. Imai K., Ochiai K. Role of histone modification on transcriptional regulation and HIV-1 gene expression: possible mechanisms of periodontal diseases in AIDS progression. J. Oral Sci. 2011, 53(1):1-13.
85. Rumbaugh G., Miller C.A. Epigenetic changes in the brain: measuring global histone modifications. Methods Mol. Biol. 2011, 670:263-274.
86. Fischer A. Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?. Neuropharmacology 2014, 80:95-102.
87. Pedersen M.T., Helin K. Histone demethylases in development and disease. Trends Cell Biol. 2010, 20(11):662-671.
88. Sawan C., Herceg Z. Histone modifications and cancer. Adv. Genet. 2010, 70:57-85.
89. Kurdistani S.K. Histone modifications in cancer biology and prognosis. Prog. Drug Res. 2011, 67:91-106.
90. Waldmann T., Schneider R. Targeting histone modifications - epigenetics in cancer. Curr. Opin. Cell Biol. 2013, 25:184-189.
91. Gezer U., Holdenrieder S. Post-translational histone modifications in circulating nucleosomes as new biomarkers in colorectal cancer. In Vivo 2014, 28(3):287-292.
92. Handy D.E., Castro R., Loscalzo J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation 2011, 123(19):2145-2156.
93. Abi Khalil C. The emerging role of epigenetics in cardiovascular disease. Ther. Adv. Chronic Dis. 2014, 5(4):178-187.
94. Sadri-Vakili G., Cha J.H. Mechanisms of disease: histone modifications in Huntington's disease. Nat. Clin. Pract. Neurol. 2006, 2(6):330-338.
95. Gray S.G. Targeting histone deacetylases for the treatment of Huntington's disease. CNS Neurosci. Ther. 2010, 16(6):348-361.
96. Lee J., Hwang Y.J., Kim K.Y., Kowall N.W., Ryu H. Epigenetic mechanisms of neurodegeneration in Huntington's disease. Neurotherapeutics 2013, 10(4):664-676.
97. Peña-Altamira L.E., Polazzi E., Monti B. Histone post-translational modifications in Huntington's and Parkinson's diseases. Curr. Pharm. Des. 2013, 19(28):5085-5092.
98. Monti B. Histone post-translational modifications to target memory-related diseases. Curr. Pharm. Des. 2013, 19(28):5065-5075.
99. Peleg S., Sananbenesi F., Zovoilis A., Burkhardt S., Bahari-Javan S., Agis-Balboa R.C., et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 2010, 328(5979):753-756.
100. Zhang H., Dai X., Qi Y., He Y., Du W., Pang J.J. Histone deacetylases inhibitors in the treatment of retinal degenerative diseases: overview and perspectives. J. Ophthalmol. 2015, 2015:250812.
101. Pelzel H.R., Nickells R.W. A role for epigenetic changes in the development of retinal neurodegenerative conditions. J. Ocul. Biol. Dis. Infor. 2011, 4(3):104-110.
102. van Bavel C.C., Dieker J.W., Kroeze Y., Tamboer W.P., Voll R., Muller S., et al. Apoptosis-induced histone H3 methylation is targeted by autoantibodies in systemic lupus erythematosus. Ann. Rheum. Dis. 2011, 70(1):201-207.
103. Tikoo K., Meena R.L., Kabra D.G., Gaikwad A.B. Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy. Br. J. Pharmacol. 2008, 153(6):1225-1231.
104. Miao F., Chen Z., Zhang L., Liu Z., Wu X., Yuan Y.C., et al. Profiles of epigenetic histone post-translational modifications at type 1 diabetes susceptible genes. J. Biol. Chem. 2012, 287(20):16335-16345.